Abstract:Modulating protein–protein interactions (PPIs) with small drug-like molecules targeting it exhibits great promise in modern drug discovery. G protein-coupled receptors (GPCRs) are the largest family of targeted proteins and could form dimers in living biological cells through PPIs. However, compared to drug development of the orthosteric site, there has been lack of investigations on the druggability of the PPI interface for GPCRs and its functional implication on experiments. Thus, in order to address these issues, we constructed a novel computational strategy, which involved in molecular dynamics simulation, virtual screening and protein structure network (PSN), to study one representative GPCR homodimer (CXCR4). One druggable pocket was identified in the PPI interface and one small molecule targeting it was screened, which could strengthen PPI mainly through hydrophobic interaction between the benzene rings of the PPI molecule and TM4 of the receptor. The PSN results further reveals that the PPI molecule could increase the number of the allosteric regulation pathways between the druggable pocket of the dimer interface to the orthostatic site for the subunit A but only play minor role for the other subunit B, leading to the asymmetric change in the volume of the binding pockets for the two subunits (increase for the subunit A and minor change for the subunit B). Consequently, the screening performance of the subunit A to the antagonists is enhanced while the subunit B is unchanged nearly, implying that the PPI molecule may be beneficial to enhance the drug efficacies of the antagonists. In addition, one main regulation pathway with the highest frequency was identified for the subunit A, which consists of Trp1955.34–Tyr190ECL2–Val1965.35–Gln2005.39–Asp2626.58–Cys28N-term, revealing their importance in the allosteric regulation from the PPI molecule. The observations from the work could provide valuable information for the development of the PPI drug-like molecule for GPCRs.

Targeting Protein-Protein Interaction by Small Molecules

Small molecules targeting protein‒protein interactions for cancer therapy

Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials

Small molecules, big targets: drug discovery faces the protein–protein interaction challenge

Rational Design of Peptide-Based Inhibitors Disrupting Protein-Protein Interactions

Development of small-molecule inhibitors that target PI3Kβ

Small Molecules Targeting Phosphoinositide 3-Kinases

Therapeutic Peptides Targeting PPI in Clinical Development: Overview, Mechanism of Action and Perspectives

Computational Modeling as a Tool to Investigate PPI: From Drug Design to Tissue Engineering

14‐3‐3 Protein‐Protein Interactions: From Mechanistic Understanding to their Small‐molecule Stabilization

Modulators of 14-3-3 Protein–Protein Interactions

Main methods and tools for peptide development based on protein-protein interactions (PPIs)

What Makes a Good Protein–Protein Interaction Stabilizer: Analysis and Application of the Dual-Binding Mechanism

Polymers for Disrupting Protein-Protein Interactions: Where Are We and Where Should We Be?

Utilization of Macrocyclic Peptides to Target Protein-Protein Interactions in Cancer.

Chemical-Protein Interactome and Its Application in Off-Target Identification

Benchmark Study Based on 2P2I(DB) to Gain Insights into the Discovery of Small-Molecule PPI Inhibitors

Probing the Druggablility on the Interface of the Protein–Protein Interaction and Its Allosteric Regulation Mechanism on the Drug Screening for the CXCR4 Homodimer

Hotspot Identification and Drug Design of Protein-Protein Interaction Modulators Using the Fragment Molecular Orbital Method

Evolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery

Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions